210 related articles for article (PubMed ID: 23459296)
1. Combination of bendamustine and entinostat synergistically inhibits proliferation of multiple myeloma cells via induction of apoptosis and DNA damage response.
Cai B; Lyu H; Huang J; Wang S; Lee CK; Gao C; Liu B
Cancer Lett; 2013 Jul; 335(2):343-50. PubMed ID: 23459296
[TBL] [Abstract][Full Text] [Related]
2. Cladribine in combination with entinostat synergistically elicits anti-proliferative/anti-survival effects on multiple myeloma cells.
Wang B; Lyu H; Pei S; Song D; Ni J; Liu B
Cell Cycle; 2018; 17(8):985-996. PubMed ID: 29969371
[TBL] [Abstract][Full Text] [Related]
3. Bendamustine induces G2 cell cycle arrest and apoptosis in myeloma cells: the role of ATM-Chk2-Cdc25A and ATM-p53-p21-pathways.
Gaul L; Mandl-Weber S; Baumann P; Emmerich B; Schmidmaier R
J Cancer Res Clin Oncol; 2008 Feb; 134(2):245-53. PubMed ID: 17653574
[TBL] [Abstract][Full Text] [Related]
4. HDAC inhibition synergistically enhances alkylator-induced DNA damage responses and apoptosis in multiple myeloma cells.
Lee CK; Wang S; Huang X; Ryder J; Liu B
Cancer Lett; 2010 Oct; 296(2):233-40. PubMed ID: 20447761
[TBL] [Abstract][Full Text] [Related]
5. [MS-275, a histone deacetylase inhibitor, induces apoptosis and alters survivin gene expression in human myeloma cell line U266].
Ma J; Zhao M; Yu XD; Wang ZH
Ai Zheng; 2009 May; 28(5):466-71. PubMed ID: 19624872
[TBL] [Abstract][Full Text] [Related]
6. Bendamustine overcomes resistance to melphalan in myeloma cell lines by inducing cell death through mitotic catastrophe.
Cives M; Ciavarella S; Rizzo FM; De Matteo M; Dammacco F; Silvestris F
Cell Signal; 2013 May; 25(5):1108-17. PubMed ID: 23380051
[TBL] [Abstract][Full Text] [Related]
7. Preclinical anti-myeloma activity of EDO-S101, a new bendamustine-derived molecule with added HDACi activity, through potent DNA damage induction and impairment of DNA repair.
López-Iglesias AA; Herrero AB; Chesi M; San-Segundo L; González-Méndez L; Hernández-García S; Misiewicz-Krzeminska I; Quwaider D; Martín-Sánchez M; Primo D; Paíno T; Bergsagel PL; Mehrling T; González-Díaz M; San-Miguel JF; Mateos MV; Gutiérrez NC; Garayoa M; Ocio EM
J Hematol Oncol; 2017 Jun; 10(1):127. PubMed ID: 28633670
[TBL] [Abstract][Full Text] [Related]
8. A monomer purified from Paris polyphylla (PP-22) triggers S and G2/M phase arrest and apoptosis in human tongue squamous cell carcinoma SCC-15 by activating the p38/cdc25/cdc2 and caspase 8/caspase 3 pathways.
Ke JY; Zhang W; Gong RS; Cen WJ; Huang HQ; Li YR; Kong WD; Jiang JW
Tumour Biol; 2016 Nov; 37(11):14863-14872. PubMed ID: 27644244
[TBL] [Abstract][Full Text] [Related]
9. Cladribine and bendamustine exhibit inhibitory activity in dexamethasone-sensitive and -resistant multiple myeloma cells.
Cai B; Wang S; Huang J; Lee CK; Gao C; Liu B
Am J Transl Res; 2013; 5(1):36-46. PubMed ID: 23390564
[TBL] [Abstract][Full Text] [Related]
10. Ricolinostat, a selective HDAC6 inhibitor, shows anti-lymphoma cell activity alone and in combination with bendamustine.
Cosenza M; Civallero M; Marcheselli L; Sacchi S; Pozzi S
Apoptosis; 2017 Jun; 22(6):827-840. PubMed ID: 28315173
[TBL] [Abstract][Full Text] [Related]
11. Inhibitors of poly ADP-ribose polymerase (PARP) induce apoptosis of myeloid leukemic cells: potential for therapy of myeloid leukemia and myelodysplastic syndromes.
Gaymes TJ; Shall S; MacPherson LJ; Twine NA; Lea NC; Farzaneh F; Mufti GJ
Haematologica; 2009 May; 94(5):638-46. PubMed ID: 19407318
[TBL] [Abstract][Full Text] [Related]
12. Combinatorial effects of histone deacetylase inhibitors (HDACi), vorinostat and entinostat, and adaphostin are characterized by distinct redox alterations.
Rivera-Del Valle N; Cheng T; Irwin ME; Donnella H; Singh MM; Chandra J
Cancer Chemother Pharmacol; 2018 Mar; 81(3):483-495. PubMed ID: 29313067
[TBL] [Abstract][Full Text] [Related]
13. [Effects of histone deacetylase inhibitor MS-275 on expression of survivin and NF-kappaB in the human myeloma cell line U266 cells].
Ma J; Zhao M; Yu XD
Zhonghua Zhong Liu Za Zhi; 2009 Apr; 31(4):250-3. PubMed ID: 19615275
[TBL] [Abstract][Full Text] [Related]
14. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
[TBL] [Abstract][Full Text] [Related]
15. Dose dependent effects on cell cycle checkpoints and DNA repair by bendamustine.
Beeharry N; Rattner JB; Bellacosa A; Smith MR; Yen TJ
PLoS One; 2012; 7(6):e40342. PubMed ID: 22768280
[TBL] [Abstract][Full Text] [Related]
16. M2, a novel anthracenedione, elicits a potent DNA damage response that can be subverted through checkpoint kinase inhibition to generate mitotic catastrophe.
Evison BJ; Pastuovic M; Bilardi RA; Forrest RA; Pumuye PP; Sleebs BE; Watson KG; Phillips DR; Cutts SM
Biochem Pharmacol; 2011 Dec; 82(11):1604-18. PubMed ID: 21889927
[TBL] [Abstract][Full Text] [Related]
17. Downregulation of Cell Cycle and Checkpoint Genes by Class I HDAC Inhibitors Limits Synergism with G2/M Checkpoint Inhibitor MK-1775 in Bladder Cancer Cells.
Hoffmann MJ; Meneceur S; Hommel K; Schulz WA; Niegisch G
Genes (Basel); 2021 Feb; 12(2):. PubMed ID: 33670166
[TBL] [Abstract][Full Text] [Related]
18. Entinostat, a novel histone deacetylase inhibitor is active in B-cell lymphoma and enhances the anti-tumour activity of rituximab and chemotherapy agents.
Frys S; Simons Z; Hu Q; Barth MJ; Gu JJ; Mavis C; Skitzki J; Song L; Czuczman MS; Hernandez-Ilizaliturri FJ
Br J Haematol; 2015 May; 169(4):506-19. PubMed ID: 25712263
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic potential of cladribine in combination with STAT3 inhibitor against multiple myeloma.
Ma J; Wang S; Zhao M; Deng XS; Lee CK; Yu XD; Liu B
BMC Cancer; 2011 Jun; 11():255. PubMed ID: 21679466
[TBL] [Abstract][Full Text] [Related]
20. Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents.
Leoni LM; Bailey B; Reifert J; Bendall HH; Zeller RW; Corbeil J; Elliott G; Niemeyer CC
Clin Cancer Res; 2008 Jan; 14(1):309-17. PubMed ID: 18172283
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
